Aurobindo Pharma Articles
India’s Aurobindo to lose $2 million a month due to US FDA ban alert
25 February 2011
Lupin may invest $50 million in Russian plant; Indian drugmakers doing well with ARVs
11 February 2011
AstraZeneca in deal with India’s Aurobindo to supply branded generics for emerging markets
6 September 2010
Showing 1-4 of 4 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
